This same molecular "on/off switch" controls immunity against many viruses, highlighting a potential new target for novel therapeutics to fight viruses, the researchers report.
In a study available online this week and in an upcoming issue of the Proceedings of the National Academy of Sciences, UT Southwestern scientists describe how the proteins RIG-I and LGP2 normally interact to turn on and off immune response to hepatitis C.
It's known that when a virus invades a cell, the RIG-I protein triggers the body to generate an immune response. Once the virus has been cleared out, the LGP2 protein turns off the RIG-I signals.
This interaction between RIG-I and LGP2 is vital for properly regulating immunity, but viruses such as hepatitis C can disrupt the normal process to shut down immune defenses early, the research team found.
"This knowledge will help us design drugs that mimic the viral effects on these proteins to either activate a host's immune response or shut it down," said Dr. Michael Gale, associate professor of microbiology and the study's senior author. "This holds great potential in developing new disease therapies, because the tactics employed by hepatitis C to trigger immune response are similar to those employed by other viruses such as West Nile, influenza and the common cold."
Dr. Gale's research centers on studying the mechanisms viruses use to evade immune defenses. Of particular interest is the hepatitis C virus, a blood-borne infection transmitted by intravenous drug use, blood transfusions and sexual contact. It affects 4 million U.S. residents and is the nation's leading cause of cirrhosis and liver cancer.
In 2005 Dr.
'"/>
Source:UT Southwestern Medical Center